Results of treatment and analysis of prognostic factors in adult patients with Ewing's sarcoma at the material of Center of Oncology in Cracow
Journal Title: Współczesna Onkologia - Year 2007, Vol 11, Issue 2
Abstract
Aim: The aim of this study is to present the results of treatment of Ewing’s sarcoma in adults at the Centre of Oncology in Cracow between 1970 and 2001. Materials and methods: There was a group of 25 adult patients: 19 males (76%) and 6 females (24%). The median age was 19 years (range: 16-42 years). In 52 patients (52%) the primary tumour was located in bones of the pelvis. At the moment of diagnosis 11 patients (44%) had metastatic disease, predominantly lung metastases. Three patients underwent surgery. All patients were given chemotherapy, and 24 patients (96%) received radiation too. In 17 patients (71%) radical radiotherapy was performed. Results: After the treatment complete regression of the tumour was achieved in 8 patients (32%). In 3 patients (12%) a partial response was obtained. Eight patients (32%) developed metastatic disease, and in 6 patients (24%) local progression was observed. Progression-free survival (PFS) and overall survival (OS) for the entire group was 20% at 5 years. In the group of 17 patients (71%) treated with radical radiation PFS and OS survival rate was 29.4 % at 5 years. An analysis of prognostic factors showed that younger age adversely affected overall survival. Better survival was found in males and in patients with localization in extremities. Analysis of therapeutic factors showed that resection of primary tumour significantly improved the results of treatment. Multiagent chemotherapy, radiation with use of 2 opposite fields and application of high dose in the tumour volume were associated with higher PFS and OS rates but differences were not statistically significant.
Authors and Affiliations
Anna Kokoszka, Beata Sas-Korczyńska, Stanisław Korzeniowski
Keywords
Related Articles
- EP ID EP159888
- DOI -
- Views 57
- Downloads 0
Zalecenia diagnostyczno-terapeutyczne dla wybranych nowotworów głowy i szyi. Wstęp
Leczenie długotrwale rozwijającego się raka podstawnokomórkowego skóry, niszczącego połowę twarzy – opis przypadku
Rak podstawnokomórkowy (ca basocellulare, basal cell epithelioma, basalioma, ulcus rodens) jest najczęstszym nowotworem skóry. Występuje przede wszystkim u mężczyzn powyżej 40. roku życia narażonych na promieniowanie sł...
Wyniki leczenia skojarzonego chemioimmunoterapią czerniaka złośliwego w IV stopniu zaawansowania klinicznego
Wstęp: Czerniak złośliwy z przerzutami odległymi uznawany jest za nowotwór wysoce oporny na leczenie. W prezentowanym badaniu autorzy podjęli próbę oceny skuteczności leczenia czerniaka złośliwego w IV stopniu zaawansowa...
Wznowa biochemiczna po radioterapii raka stercza
Wznowa biochemiczna 5 lat po teleradioterapii lub brachyterapii występuje u 5–20 proc. pacjentów z I grupy prognostycznej oraz u 30–60 proc. chorych z II i III grupy prognostycznej. Wyniki napromieniania oceniane są na p...
Irinotecan in chemotherapy of advanced colorectal cancer
Irinotecan (CPT-11) is a semisynthetic derivative of camptothecin, which effectiveness and toxicity have been extensively investigated in colorectal cancer (crc) and in this type of neoplasm it has wide application. Prom...